|
Market Closed -
Nasdaq
01:30:00 20/08/2026 am IST
|
5-day change | 1st Jan Change | ||
| 840.84 USD | +3.78% |
|
+5.37% | +8.94% |
| 19/08 | Regeneron Pharmaceuticals Wins US FDA Approval For Pasatru In Ultra-Rare Musculoskeletal Condition | MT |
| 19/08 | US FDA approves Regeneron's rare bone disorder drug | RE |
| Market Cap | 8.4TCr 7.2TCr 6.73TCr 6.17TCr 12TCr 8,02500Cr 12TCr 79TCr 31TCr 4,02500Cr 32TCr 31TCr 13,30800Cr | P/E 2026 * |
19.5x | P/E 2027 * | 16.7x |
|---|---|---|---|---|---|
| Enterprise Value | 7.71TCr 6.61TCr 6.18TCr 5.67TCr 11TCr 7,36900Cr 11TCr 73TCr 29TCr 3,69600Cr 29TCr 28TCr 12,21900Cr | EV / Sales 2026 * |
4.56x | EV / Sales 2027 * | 3.99x |
| Free-Float |
71.07% | Yield 2026 * |
0.46% | Yield 2027 * | 0.53% |
Last Transcript: Regeneron Pharmaceuticals, Inc.
| 1 day | +3.78% | ||
| 1 week | +5.37% | ||
| Current month | +10.26% | ||
| 1 month | +24.26% | ||
| 3 months | +33.40% | ||
| 6 months | +7.47% | ||
| Current year | +8.94% |
| 1 week | 792.57 |  | 844.92 |
| 1 month | 637.8 | | 844.92 |
| Current year | 591.52 | | 844.92 |
| 1 year | 541 | | 844.92 |
| 3 years | 476.49 | | 1,211.2 |
| 5 years | 476.49 | | 1,211.2 |
| 10 years | 271.37 | | 1,211.2 |
| Manager | Title | Age | Since |
|---|---|---|---|
| President | 66 | 01/01/2001 | |
| Chief Executive Officer | 73 | 08/01/1988 | |
| Director of Finance/CFO | 55 | 05/02/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 73 | 09/06/2023 | |
Michael Brown
BRD | Director/Board Member | 85 | 01/06/1991 |
Joseph Goldstein
BRD | Director/Board Member | 85 | 01/06/1991 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 10/08/26 | Fiscal year | Director | 1,200 | 0.0012% | ||
| 10/08/26 | Fiscal year | Director | 2,400 | 0.0023% | ||
| 02/07/26 | Sell | Director | -200 | 0.0002% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +3.78% | +5.37% | +47.06% | +3.50% | 8.09TCr | |
| +4.95% | +27.08% | -20.83% | -34.51% | 5.36TCr | |
| +0.85% | -0.32% | -1.93% | +30.25% | 5.01TCr | |
| +0.23% | -1.80% | +13.14% | +170.56% | 4.8TCr | |
| +4.24% | +6.08% | +59.56% | -15.16% | 3.14TCr | |
| +176.97% | +173.88% | +524.79% | +71.60% | 2.51TCr | |
| +4.05% | +6.38% | +50.33% | +100.61% | 2.5TCr | |
| +5.65% | +9.09% | +9.67% | +233.23% | 2.15TCr | |
| +0.22% | +4.68% | +66.64% | +127.79% | 1.69TCr | |
| +1.17% | +0.13% | +71.64% | +192.31% | 1.62TCr | |
| Average | +2.15% | +21.02% | +82.01% | +88.02% | 3.69TCr | |
| Weighted average by Cap. | +2.47% | +16.07% | +59.77% | +60.35% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 1.69TCr 1.45TCr 1.36TCr 1.24TCr 2.34TCr 1,61700Cr 2.38TCr 16TCr 6.26TCr 81TCr 6.35TCr 6.22TCr 2,68200Cr | 1.84TCr 1.58TCr 1.48TCr 1.35TCr 2.55TCr 1,76000Cr 2.59TCr 17TCr 6.82TCr 88TCr 6.92TCr 6.77TCr 2,91900Cr |
| Net income | 477.34Cr 409.46Cr 382.34Cr 350.79Cr 659.65Cr 46TCr 670.51Cr 4.51TCr 1.77TCr 23TCr 1.79TCr 1.75TCr 76TCr | 544.54Cr 467.11Cr 436.17Cr 400.18Cr 752.52Cr 52TCr 764.91Cr 5.15TCr 2.02TCr 26TCr 2.04TCr 2TCr 86TCr |
| Net Debt | -686.84Cr -589.17Cr -550.15Cr -504.75Cr -949.17Cr -66TCr -964.8Cr -6.49TCr -2.54TCr -33TCr -2.58TCr -2.52TCr -1,08900Cr | -1.06TCr -905.31Cr -845.35Cr -775.59Cr -1.46TCr -1,00900Cr -1.48TCr -9.97TCr -3.91TCr -51TCr -3.96TCr -3.88TCr -1,67300Cr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 19/26/19 | $840.84 | +3.78% | 7,50,394 |
| 18/26/18 | $810.24 | +0.53% | 7,79,072 |
| 17/26/17 | $805.93 | +0.30% | 5,41,306 |
| 14/26/14 | $803.48 | -0.31% | 4,25,600 |
| 13/26/13 | $805.97 | +1.00% | 7,09,747 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- REGN Stock
Select your edition
All financial news and data tailored to specific country editions
